Emerging drugs of abuse

Medical Clinics of North America

Volumn 89, Issue 6, 2005, Pages 1259-1276

  Haroz, Rachel ^a   Greenberg, Michael I ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ANTITUSSIVE AGENT; BENZODIAZEPINE DERIVATIVE; BROMIDE; CATHA EDULIS EXTRACT; CORICIDIN; DEXTROMETHORPHAN; FENTANYL; FENTANYL CITRATE; GUAIFENESIN; HERBACEOUS AGENT; ILLICIT DRUG; METHAMPHETAMINE; MORPHINE; N ETHYL 3,4 METHYLENEDIOXYAMPHETAMINE; NALOXONE; PARACETAMOL; PHENETHYLAMINE; PHENETHYLAMINE DERIVATIVE; PIPERAZINE DERIVATIVE; TRYPTAMINE DERIVATIVE;

AGITATION; ANXIETY; ATAXIA; CANCER PAIN; CENTRAL NERVOUS SYSTEM DEPRESSION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; DIAPHORESIS; DRUG ABUSE; DRUG INTOXICATION; DRUG OVERDOSE; EUPHORIA; FASCICULATION; HALLUCINATION; HEADACHE; HUMAN; HYPERREFLEXIA; HYPERTENSION; HYPOTENSION; LETHARGY; MIOSIS; MUSCLE HYPERTONIA; NAUSEA; NONHUMAN; NYSTAGMUS; PRIORITY JOURNAL; RESPIRATION DEPRESSION; REVIEW; SALVIA; SEIZURE; SIDE EFFECT; SLURRED SPEECH; SUBSTANCE ABUSE; TACHYCARDIA; TREMOR; VOMITING;

HUMANS; PHENETHYLAMINES; PIPERAZINES; POISONING; STREET DRUGS; TRYPTAMINES; UNITED STATES;

EID: 26844529749     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2005.06.008     Document Type: Review

References (65)

1. Drug Enforcement Administration/Department of Justice. Intelligence brief. Ecstasy: rolling across Europe. August 2001.
2. Drug Enforcement Administration/Department of Justice DEA notice of intent to schedule alpha-methyltryptamine and 5-methoxy-N, N- diisopropyltryptamine Fed Regist 68 18 2003
3. Drug Enforcement Agency. Drug intelligence brief. Trippin'on tryptamines. October 2003.
4. J.H. Halpern Hallucinogens and dissociative agents naturally growing in the United States Pharmacol Ther 102 2004 131 138
5. E.A. Carlini Plants and the central nervous system Pharmacol Biochem Behav 75 2003 501 512
6. S.C. Smolinske, R. Rastogi, and S. Schenkel Foxy methoxy: a new drug of abuse Int J Med Toxicol 7 1 2004 3
7. R. Meatherall, and P. Sharma Foxy, a designer tryptamine hallucinogen J Anal Toxicol 27 2003 313 317
8. R.M. Dailey, L.D. Nelson, and J.M. Scaglione Tachycardia and rhabdomyolysis after intentional ingestion of N,N-dipropyltryptamine J Toxicol Clin Toxicol 41 2003 742
9. H. Long, L.S. Nelson, and R.S. Hoffman Alpha-methyltryptamine revisited via easy Internet access Vet Hum Toxicol 45 3 2003 149
10. National Drug Intelligence Center. 5-MeO-AMT fast facts. 2004.
11. R.A. Glennon Classical hallucinogens: an introductory overview NIDA Res Monogr 146 1994 9 37
12. A.S. Christopherson Amphetamine designer drugs - an overview and epidemiology Toxicol Lett 112 2000 127 131
13. D. De Boer, M.J. Gijzels, and I.J. Bosman More data about the new psychoactive drug 2C-B J Anal Toxicol 23 3 1999 227 228
14. D. De Boer, and I. Bosman A new trend in drugs-of-abuse: the 2C-series of phenethylamine designer drugs Pharm World Sci 26 2004 110 113
15. European Monitoring Centre for Drugs and Drug Addiction. Report on the risk assessment of 2C-I, 2C-T-2, and 2C-T-7 in the framework of the joint action on new synthetic drugs. 2004.
16. Drug Enforcement Administration/Department of Justice. Schedules of controlled substances: placement of 4-bromo-2,5-dimethoxyphenethylamine into schedule I. June 2, 1995.
17. Curtis B, Harty L, Kemp P, et al. Preliminary investigation into identification and quantitation of 2,5 dimethoxy-N-propylthiophenethylamine also known as 2 C-T-7. Presented at the Fall Meeting of the Southwestern Association of Toxicologists. San Antonio (TX), November 1-3, 2001.
18. US Department of Justice. Information bulletin. 2C-B (Nexus) reappears on the club drug scene. May 2001.
19. D. De Boer, I.J. Bosman, and E. Hidvegi Piperazine-like compounds: a new group of designer drugs-of-abuse on the European market Forensic Sci Int 121 2001 47 56
20. M. Wikstrom, P. Holmgren, and J. Ahlner A2 (N-benzylpiperazine): a new drug of abuse in Sweden J Anal Toxicol 28 1 2004 67 70
21. H.H. Maurer, T. Kraemer, and D. Springer Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (Ecstasy), piperazine, and pyrrolidinophenone types Ther Drug Monit 26 2 2004 127 131
22. The vaults of EROWID. BZP. Available at: http://www.erowid.org/chemicals/ bzp/bzp.shtml. Accessed December 2004.
23. M. Bauman, R.D. Clark, and A.G. Budzynski N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4- methylenedioxymethamphetamine (MDMA, or "Ecstasy") Neuropsychopharmacology 30 3 2005 550 560
24. Drug Enforcement Administration (DEA), Department of Justice. Schedules of controlled substances; placement of 2,5-dimethoxy-4-(n)- propylthiophenethylamine and N-benzylpiperazine into Schedule I of the Controlled Substances Act. Final rule Fed Regist 69 53 2004 12794 12797
25. Drug Enforcement Administration (DEA). Benzylpiperazine, trifluoromethylphenylpiperazine (BZP, TFMPP). Drugs and chemicals of concern. 2001.
26. C. Balmelli, H. Kupferschmidt, and K. Reutsch Fatal brain oedema after ingestion of ecstasy and benzylpiperazine Dtsch Med Wochenschr 126 2001 809 811
27. The Expert Advisory Committee on Drugs (EACD) advice to the Minister on: benzylpiperazine (BZP). April 2004.
28. Drug Enforcement Administration/Department of Justice. Drug intelligence brief. BZP and TFMPP: chemicals used to mimic MDMA's effects. December 2001.
29. R. Paris Abyssinian tea (Catha edulis Forssk, Celastraceae) United Nations Office on Drugs and Crime - Bulletin on Narcotics 2 1958 29 34
30. Drug Enforcement Administration/Department of Justice Drug intelligence brief Khat June 2002
31. S.W. Toennes, S. Harder, and M. Schramm Pharmacokinetics of cathinone, cathine, and norephedrine after chewing of khat leaves Br J Clin Pharmacol 56 2003 125 130
32. C. Pantelis, C. Hindler, and J. Taylor Use and abuse of khat (catha edulis): a review of the distribution, pharmacology, side effects and description of psychosis attributed to khat chewing Psychol Med 19 3 1989 657 668
33. F. Sporkert, F. Pragst, and R. Bachus Determination of cathinone, cathine and norephedrine in hair of Yemenite khat chewers Forensic Sci Int 133 2003 39 46
34. "Graba" (dried khat) seized in Kansas City. Intelligence brief NDIC Narcotics Digest Weekly 3 13 2004 3
35. Spinella M. Psychopharmacology of herbal medicine. Cambridge (MA): MIT Press; 2001.
36. S.W. Toennes, and G.F. Kauert Driving under the influence of khat - alkaloid concentrations and observations in forensic cases Forensic Sci Int 140 2004 85 90
37. A. Al-Motarreb, M. Al-Kebsi, and B. Al-Adhi Khat chewing and acute myocardial infarction Heart 87 2002 279 280
38. F. Kassie, F. Darroudi, and M. Kundi Khat (Catha edulis) consumption causes genotoxic effects in humans Int J Cancer 92 2001 329 332
39. National Drug Intelligence Center. Department of Justice information bulletin. Salvia divinorum. April 2003.
40. Leinwand D. Teens, and now DEA, are on trail of hallucinogenic herb. USA Today. June 22, 2003.
41. The vaults of EROWID. Salvia divinorum. Available at: http://www.erowid.org/plants/salvia/salvia.shtml. Accessed December 2004.
42. C. Giroud, F. Felber, and M. Augsburger Salvia divinorum: an hallucinogenic mint which might become a new recreational drug in Switzerland Forensic Sci Int 112 2000 143 150
43. Drug Enforcement Administration. Salvia divinorum. Drugs and chemicals of concern. June 2004.
44. L.J. Valdes, H.M. Chang, and D.C. Visger Salvinorin C, a new neoclerodane diterpene from a bioactive fraction of the hallucinogenic Mexican mint Salvia divinorum Org Lett 3 24 2001 3935 3937
45. B.L. Roth, K. Baner, and R. Westkaemper Salvinorin A: a potent naturally occurring nonnitrogenous κ opioid selective agonist Proc Natl Acad Sci U S A 99 2002 11934 11939
46. T. Wolfe, and E. Caravati Massive dextromethorphan ingestion and abuse Am J Emerg Med 13 1995 174 175
47. W. Noonan, W. Miller, and D. Feeney Dextromethorphan abuse among youth Arch Fam Med 9 2000 790 793
48. The vaults of EROWID. DXM dosage. Available at: http://www.erowid.org/ chemicals/dxm/dxm_dose.shtml. Accessed December 2004.
49. J.L. Bern, and R. Peck Dextromethorphan: an overview of safety issues Drug Saf 7 1992 190 199
50. L. Zawertailo, H.L. Kaplan, and U.E. Busto Psychotropic effects of dextromethorphan are altered by the CYP2D6 polymorphism: a pilot study J Clin Psychopharmacol 18 1998 332 337
51. E. Pender, and B. Parks Toxicity with dextromethorphan-containing preparations: a literature review and report of two additional cases Pediatr Emerg Care 7 3 1991 163 165
52. T. Kirages, H. Sule, and M. Mycyk Severe manifestations of coricidin intoxication Am J Emerg Med 21 2003 473 475
53. L. Price, and J. Lebel Dextromethorphan-induced psychosis Am J Psychiatry 157 2 2000 304
54. J. Shier, and J. Diaz Avoid unfavorable consequences: dextromethorphan can bring about a false positive phencyclidine urine drug screen J Emerg Med 18 3 2000 379 383
55. S. Schneider, E.A. Michelson, and C.D. Boucek Dextromethorphan poisoning reversed by naloxone Am J Emerg Med 9 1991 237 238
56. A. Poklis Fentanyl: a review for clinical and analytical toxicologists J Toxicol Clin Toxicol 33 5 1995 439 448
57. Drug Enforcement Administration. Fentanyl. Drugs and chemicals of concern. DEA Diversion Program. October 2004.
58. K.A. Marquardt, and S.R. Tharratt Inhalation abuse of fentanyl patch J Toxicol Clin Toxicol 32 1 1994 75 79
59. F.J. Barrueto The fentanyl tea bag Vet Hum Toxicol 46 1 2004 30 31
60. C. Kramer, and M. Tawney A fatal overdose of transdermally administered fentanyl J Am Osteopath Assoc 98 7 1998 385 386
61. M. Purucker, and W. Swann Potential for duragesic patch abuse Ann Emerg Med 35 3 2000 314
62. A.M. Tharp, R.E. Winecker, and D.C. Winston Fatal intravenous fentanyl abuse Am J Forensic Med Pathol 25 2 2004 178 181
63. M.D. Reeves, and C.J. Ginifer Fatal intravenous misuse of transdermal fentanyl Med J Aust 177 2002 552 553
64. Lollipop-shaped fentanyl products diverted in Eastern Pennsylvania. DEA microgram bulletin June 2004 Narcotics Digest Weekly 3 20 2004 1
65. M. Grossmann, A. Abiose, and O. Tangphao Morphine-induced venodilation in humans Clin Pharmacol Ther 60 5 1996 554 560